Trastuzumab in the treatment of advanced non-small-cell lung cancer: Is there a role? Focus on Eastern Cooperative Oncology Group Study 2598

Medicine & Life Sciences

• Trastuzumab 100%
• Non-Small Cell Lung Carcinoma 75%
• Paclitaxel 56%
• Carboplatin 52%
• Stroke Volume 16%
• Therapeutics 13%
• Survival 10%
• Arthralgia 9%
• Peripheral Nervous System Diseases 9%
• Neutropenia 9%
• Thrombocytopenia 8%
• Progression-Free Survival 8%
• Nausea 8%
• Fatigue 7%
• Area Under Curve 7%
• Survival Rate 7%
• Bone Marrow 6%
• Maintenance 6%
• Cell Line 5%
• Kidney 5%
• Liver 4%
• Growth 4%
• Incidence 4%
• In Vitro Techniques 4%
• Neoplasms 3%